The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade

Title: The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade

Volume: 5 Issue: 2

Author(s): Steven G. Chrysant, George S. Chrysant, Catherine Chrysant and Mohammad Shiraz

Affiliation:

Keywords: Cardiovascular disease continuum, cholesterol, diabetes, hypertension, obesity, ACE inhibitors, ARBs

Abstract: The cardiovascular disease continuum is a sequence of events, which begins with a host of risk factors consisting of diabetes mellitus, dyslipidemia, hypertension, smoking and visceral obesity. If left untreated, it will inexorably progress to atherosclerosis, CAD, myocardial infarction, left ventricular remodeling, LVH, left ventricular enlargement, and eventually end-stage heart failure and death. Treatment intervention at any stage of its course will prevent or delay its further progression. However, the best results are expected to be achieved when treatment is initiated at the beginning, or at an early stage of its course. A Pub-Med/MEDLINE search was conducted for relevant English language, randomized clinical trials and epidemiologic studies for the years 1995-2009 using the terms, cardiovascular continuum, obesity, hyperlipidemia, diabetes mellitus, hypertension, metabolic syndrome, renal disease, stroke, and blockers of the renin angiotensin system (RAS). A total of 34 pertinent studies were selected for review. This concise review will focus on prevention and the aggressive treatment of the existing cardiovascular risk factors with emphasis on the blockers of RAS, and demonstrate that RAS blockers are the best drugs for its treatment.

Cite this article as:

G. Chrysant Steven, S. Chrysant George, Chrysant Catherine and Shiraz Mohammad, The Treatment of Cardiovascular Disease Continuum: Focus on Pharmacologic Management and RAS Blockade, Current Clinical Pharmacology 2010; 5 (2) . https://dx.doi.org/10.2174/157488410791110742